ABCL
NASDAQAbCellera Biologics Inc.
Website
News25/Ratings12
Price$4.18-0.12 (-2.68%)
2026-01-212026-04-24
News · 26 weeks31+100%
2025-10-262026-04-19
Mix1090d
- Earnings3(30%)
- SEC Filings3(30%)
- Insider3(30%)
- Other1(10%)
Latest news
25 items- PRAbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings CallAbCellera (NASDAQ:ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement data, during its first quarter 2026 earnings call on Monday, May 11, 2026. ABCL635 is a potential first-in-class antibody therapeutic targeting the neurokinin 3 receptor (NK3R) for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. It is currently being evaluated in a Phase 1/2 study, and the results of the ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 portion in postmenopausal women with moderate-
- PRAbCellera to Report First Quarter 2026 Financial Results on May 11, 2026AbCellera (NASDAQ:ABCL) will announce its first quarter 2026 financial results on Monday, May 11, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women's health, immunology, oncology, and more. For more in
- INSIDERLarge owner Thermopylae Holdings Ltd. bought $130,720 worth of shares (38,000 units at $3.44), increasing direct ownership by 0.07% to 56,134,097 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERLarge owner Thermopylae Holdings Ltd. bought $580,284 worth of shares (177,457 units at $3.27), increasing direct ownership by 0.32% to 56,096,097 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERChief Financial Officer Booth Andrew bought $145,692 worth of shares (42,600 units at $3.42), increasing direct ownership by 28% to 195,600 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- SECSEC Form S-8 filed by AbCellera Biologics Inc.S-8 - AbCellera Biologics Inc. (0001703057) (Filer)
- SECSEC Form 10-K filed by AbCellera Biologics Inc.10-K - AbCellera Biologics Inc. (0001703057) (Filer)
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Reports Full Year 2025 Business ResultsAbCellera (NASDAQ:ABCL) today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2025, AbCellera successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the year with approximately $700 million in available liquidity to execute on our strategy," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "We entered 2026 with a fully built platform, a growing pipeline with multiple potential first-in-class programs and important near-term clinical readouts, and sufficient liquidity to fund well beyond the next three years of p
- PRAbCellera to Present at Upcoming Investor Conferences in March and April 2026AbCellera (NASDAQ:ABCL) today announced that the Company will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference, March 4, 2026 KeyBanc Capital Markets Healthcare Forum, March 17, 2026 Bloom Burton & Co. Healthcare Investor Conference, April 21-22, 2026 A live audio webcast of each presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website closer to date. A replay will be available through the same link following the presentation. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines i
- PRAbCellera to Report Full Year 2025 Financial Results on February 24, 2026AbCellera (NASDAQ:ABCL) will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please v
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to MenopauseAbCellera (NASDAQ:ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. ABCL635 is a potential first-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause. The transition to Phase 2 follows an interim review of safety, tolerability, and pharmacodynamic data from healthy volunteers from the Phase 1 portion of the study. The Phase 2 portion is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of ABCL635 in reducing the frequency and severity of VMS in 80 postmenopausal women. "Advancing this program into P
- INSIDERSEC Form 4 filed by Chief Financial Officer Booth Andrew4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Hansen Carl L. G.4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer Stimart Tryn4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERSEC Form 4 filed by Chief Technology Officer Lecault Veronique4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERSEC Form 4 filed by Director Quake Stephen4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERNew insider Quake Stephen claimed ownership of 1,100,436 shares (SEC Form 3)3 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERLarge owner Thermopylae Holdings Ltd. gifted 225,000 shares, decreasing direct ownership by 0.40% to 55,918,640 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera and Bruker Reach Global Settlement of Patent LitigationAbCellera (NASDAQ:ABCL) today announced that it has entered into a settlement and patent license agreement with Bruker Corporation, resolving the patent litigation between the two companies globally. As part of the settlement, Bruker will pay AbCellera $36 million up front as well as future royalty payments on sales of Bruker's Beacon® Optofluidic platform products worldwide through the life of the licensed patents. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcel
- PRAbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026AbCellera (NASDAQ:ABCL) today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com. View source version on businesswire.com: https://www.
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- INSIDERDirector Montalbano John S. bought $178,460 worth of shares (50,000 units at $3.57), increasing direct ownership by 29% to 221,000 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)